This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis (RM/NEB-03-10)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2011 by Erempharma.
Recruitment status was:  Recruiting
Sponsor:
Collaborators:
University of Lyon
Epidemiologie Pharmacologie Investigation Clinique Information medicale Mere Enfant (EPICIME)
Clininfo S.A.
Hospices Civils de Lyon
Information provided by:
Erempharma
ClinicalTrials.gov Identifier:
NCT01337219
First received: April 13, 2011
Last updated: April 15, 2011
Last verified: February 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Study Completion Date: No date given
  Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)